CAPMUL® — Where Formulation Begins™

Article

ABITEC’s CAPMUL bioavailability enhancers are medium-chain mono- and di-glycerides and propylene glycol esters. These functional lipid excipients act as solubilizers and emulsifiers in oral, topical, transdermal, and parenteral drug delivery systems.

 

 

ABITEC’s CAPMUL bioavailability enhancers are medium-chain mono- and di-glycerides and propylene glycol esters. These functional lipid excipients act as solubilizers and emulsifiers in oral, topical, transdermal, and parenteral drug delivery systems. CAPMUL excipients are recognized as the ideal starting point when formulating BCS Class II (poorly water soluble) and BCS Class IV (poorly permeable) molecules. Lipid based drug delivery systems may be formulated as liquid or semi-solid formulations for oral dosage forms, as well as creams and ointments for topical and transdermal applications.
 

CAPMUL may be used as a majority component in solubilization/emulsification formulations. CAPMUL based formulations may also be customized with the inclusion of CAPTEX®medium-chain triglycerides and/or ACCONON®nonionic surfactants, added for enhanced bioavailability.
 

ABITEC manufactures CAPMUL, CAPTEX and ACCONON high-quality lipid excipients for drug delivery applications in accordance with strict cGMP and applicable IPEC (International Pharmaceutical Excipient Council) guidelines in ISO certified facilities. ABITEC’s customer-preferred portfolio of pharmaceutical excipients are monograph compliant, supported by drug master files (DMFs), and have precedence of use.
 

Contact Details:

ABITEC Corporation
501 W. 1ST Ave.
Columbus, OH 43215 USA
Website:www.abiteccorp.comE-mail:sales@abiteccorp.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content